Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214317
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
DC FieldValueLanguage
dc.contributor.authorHidalgo-Tenorio, Carmen-
dc.contributor.authorLópez-Cortés, Luis Eduardo-
dc.contributor.authorGutiérrez, Alicia R.-
dc.contributor.authorSantos, Jesús-
dc.contributor.authorOmar, Mohamed-
dc.contributor.authorGálvez Contreras, María Carmen-
dc.contributor.authorSequera, Sergio-
dc.contributor.authorJesus, Samantha E. de-
dc.contributor.authorTéllez, Francisco-
dc.contributor.authorFernández, Elisa-
dc.contributor.authorGarcía, Coral-
dc.contributor.authorPasquau-Liaño, Juan-
dc.date.accessioned2020-06-15T08:45:03Z-
dc.date.available2020-06-15T08:45:03Z-
dc.date.issued2019-08-
dc.identifierdoi: 10.1097/MD.0000000000016813-
dc.identifierissn: 0025-7974-
dc.identifiere-issn: 1536-5964-
dc.identifier.citationMedicine 98(32): e16813 (2019)-
dc.identifier.urihttp://hdl.handle.net/10261/214317-
dc.description.abstractDolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis. We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VL < 50 copies/mL at week 48, and on associated adverse effects. The 177 HIV+ patients were collected, 77.4% male, with average age of 48.5 years and mean count of 252.2cell/μL CD4+ nadir lymphocytes; 96.6% had VL < 50 copies/mL and 674 cells/μL CD4+ lymphocytes. Median time since HIV diagnosis was 15 years, and median ART duration was 13 years, and 34.5% of patients were on mono- or dual-therapy before the switch. At week 48, 82.4% of patients had VL < 50 cop/μL using an intention-to-treat (ITT) analysis, 89.6% according to mITT, and 96.7% according to Per-Protocol analysis. 3.3% patients had virological failure (VF). These effectiveness data and costs were compared with those for 2 reference triple therapies (DTG/ABC/3TC and EVG/cobi/FTC/TAF) in a cost minimization analysis, showing cost savings with administration of DTG+3TC (2741 €/year vs DTG/ABC/3TC and 4164 €/year vs EVG/cobi/FTC/TAF) and in a cost-effectiveness analysis, finding the DT to be the most cost-effective approach (ICER = −548 vs DTG/ABC/3TC and ICER = −4,627€ vs EVG/cobi/FTC/TAF) The combination of 3TC with DTG appears to be a safe and effective option for the simplification of ART in pretreated and virologically stable HIV-positive patients, being cost-effective and offering the same effectiveness as the triple therapy it replaces.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectDOLAMA-
dc.subjectDolutegravir-
dc.subjectDual therapy-
dc.titleDOLAMA study. Effectiveness, safety and pharmacoeconoSequera, Sergio mic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients-
dc.typeartículo-
dc.identifier.doi10.1097/MD.0000000000016813-
dc.relation.publisherversionhttp://dx.doi.org/10.1097/MD.0000000000016813-
dc.date.updated2020-06-15T08:45:03Z-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0-
dc.relation.csic-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.openairetypeartículo-
item.cerifentitytypePublications-
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat
DOLAMA_study__Effectiveness,_safety_and.72.pdf266,79 kBAdobe PDFThumbnail
View/Open
Show simple item record

WEB OF SCIENCETM
Citations

15
checked on Nov 23, 2021

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.